All In Biotech

Drug Trial Radar · NCT06447480

Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients

Randomized Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients: ETHNIC Study

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Sep 1, 2027

Study completion Sep 1, 2028

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 13 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In Dermatology, assessment of people of color remains underrepresented in RCTs (\<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420

Conditions

  • Acne Vulgaris

Interventions

  • ISOtretinoin 5 MGDrug

    The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d. After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended.

  • Topical creamDrug

    Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity of score acne-related pigmentationTime frame: at 6 months

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • CH D'argenteuil

    Argenteuil, France · Recruiting

  • Cabinet Dermatologique Brest 1

    Brest, France · Recruiting

  • Cabinet Dermatologique Brest 2

    Brest, France · Recruiting

  • Cabinet dermatologique Cenon

    Cenon, France · Not yet recruiting

  • Cabinet dermatologique gradignan

    Gradignan, France · Recruiting

  • CHU de la réunion

    La Réunion, France · Recruiting

  • Ambroise paré

    Paris, France · Recruiting

  • Cabinet dermatologique privé

    Paris, France · Not yet recruiting

  • Cabinet dermatologique

    Paris, France · Recruiting

  • CH Avicenne - APHP

    Paris, France · Recruiting

  • CHU de Poitiers

    Poitiers, France · Recruiting

  • CHU de Nice - Hôpital de l'Archet

    Nice, Alpes-Maritimes, France · Recruiting

  • CHU de Bordeaux

    Bordeaux, Aquitaine, France · Recruiting

  • APHP

    Paris, Île-de-France Region, France · Recruiting

  • CHU de Nantes

    Nantes, Loire-Atlantique, France · Recruiting

  • chu de Rouen

    Rouen, Seine-maritime, France · Recruiting

  • Cabinet de dermatologie St Maxime

    Sainte-Maxime, Var, France · Recruiting

  • CH de Cayenne 3 Avenue Alexis Blaise, BP6006

    Cayenne, French Guiana · Recruiting

  • Cabinet de dermatologie DERMACLINIC 972

    Fort-de France, French Guiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.